/FNAM
FNAM Stock - Evolutionary Genomics, Inc.
Healthcare|BiotechnologyOTC
$0.00+0.00%
+$0.00 (+0.00%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.22
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for FNAM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.04
52W High$0.45
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $12,500 | $122,686 | $114,814 |
| Gross Profit | $-1,021,493 | $-1,038,816 | $-1,780,645 | $-83,142 | $114,814 |
| Gross Margin | N/A | N/A | -14245.2% | -67.8% | 100.0% |
| Operating Income | $-2,014,302 | $-2,877,943 | $-2,879,795 | $-774,825 | $-836,799 |
| Net Income | $-1,934,967 | $-2,793,944 | $-1,711,883 | $-793,140 | $-1,098,617 |
| Net Margin | N/A | N/A | -13695.1% | -646.5% | -956.9% |
| EPS | $-0.35 | $-0.52 | $-0.34 | $-0.13 | $-0.19 |
Company Overview
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governmental organizations, non-profit foundations, and commercial entities. Evolutionary Genomics, Inc. was incorporated in 1990 and is based in Castle Rock, Colorado.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
FNAMBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.04
Q1 2023
EPS Surprise History
Q2 21
No data
Q3 21
No data
Q4 21
No data
Q1 22
No data
Q2 22
No data
Q3 22
No data
Q4 22
No data
Q1 23
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2024 | Nov 18, 2024 | — | — | — | — |
Q3 2024 | Aug 28, 2024 | — | — | — | — |
Q2 2024 | May 10, 2024 | — | — | — | — |
Q1 2024 | Feb 12, 2024 | — | — | — | — |
Q4 2023 | Nov 27, 2023 | — | — | — | — |
Q2 2023 | May 30, 2023 | — | — | — | — |
Q2 2023 | Apr 8, 2023 | — | — | — | — |
Q1 2023 | Mar 9, 2023 | — | $-0.04 | — | — |
Q4 2022 | Oct 21, 2022 | — | $-0.08 | — | — |
Q3 2022 | Aug 8, 2022 | — | $-0.08 | — | — |
Q2 2022 | May 16, 2022 | — | $-0.09 | — | — |
Q1 2022 | Mar 21, 2022 | — | $-0.11 | — | — |
Q4 2021 | Nov 1, 2021 | — | $-0.18 | — | — |
Q3 2021 | Aug 6, 2021 | — | $-0.09 | — | — |
Q2 2021 | May 13, 2021 | — | $-0.09 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.29 | — | — |
Q4 2020 | Nov 13, 2020 | — | $0.09 | — | — |
Q3 2020 | Aug 19, 2020 | — | $-0.05 | — | — |
Q2 2020 | May 12, 2020 | — | $-0.04 | — | — |
Q1 2020 | Mar 30, 2020 | — | $-0.04 | — | — |
Latest News
Loading news...
Frequently Asked Questions about FNAM
What is FNAM's current stock price?
Evolutionary Genomics, Inc. (FNAM) is currently trading at $0.00 per share. The stock has moved +0.00% today.
What is the analyst price target for FNAM?
No analyst price targets are currently available for this stock.
What sector is Evolutionary Genomics, Inc. in?
Evolutionary Genomics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is FNAM's market cap?
Evolutionary Genomics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does FNAM pay dividends?
No, Evolutionary Genomics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLABF
Core One Labs Inc.
$0.00
Mkt Cap: $0.0B
DOSEF
Doseology Sciences Inc.
$0.05
Mkt Cap: $0.0B
ENZN
Enzon Pharmaceuticals, Inc.
$0.04
Mkt Cap: $0.0B
HLYK
HealthLynked Corp.
$1.81
Mkt Cap: $0.0B
LIFD
LFTD Partners Inc.
$0.23
Mkt Cap: $0.0B
REPCF
RepliCel Life Sciences Inc.
$0.00
Mkt Cap: $0.0B
RSCF
Reflect Scientific, Inc.
$0.05
Mkt Cap: $0.0B
SIGY
Sigyn Therapeutics, Inc.
$1.71
Mkt Cap: $0.0B
SRNE
Sorrento Therapeutics, Inc.
$0.00
Mkt Cap: $0.0B
TDSGF
Telo Genomics Corp.
$0.04
Mkt Cap: $0.0B
Explore stocks similar to FNAM for comparison